Bacopa monnieri, also known as Brahmi or Waterhyssop, is a plant used in Ayurveda for its memory-enhancing properties and control of blood sugar levels. It contains active compounds such as alkaloids, saponins, and cucurbitacins, which have various biological activities. The plant has been studied for its potential in treating Alzheimer’s disease, Parkinson’s disease, attention deficit hyperactivity disorder (ADHD), and depression. Animal studies have shown promising results in reducing symptoms and protecting against neurodegeneration. Concerning safety, Bacopa monnieri has been found to be generally non-toxic, with no serious side effects reported. However, interactions with certain medications and contraindications in conditions like hyperthyroidism should be considered. Further research is needed to determine optimal dosages and ensure safety, especially for pregnant and breastfeeding women.

Cannabidiol (CBD), a phytocannabinoid with therapeutic potential for neurological and other conditions, faces significant challenges in bioavailability due to its low water solubility, high lipophilicity, and extensive first-pass metabolism. Researchers have developed advanced nanodelivery systems addressing these limitations to enhance CBD’s absorption, stability, and efficacy. This review provides not only a comprehensive summary of current nanotechnological delivery strategies for CBD, including nanoemulsions, liposomes, polymeric micelles, nanosuspensions, and cyclodextrin inclusion complexes, but also introduces a distinct comparative and integrative perspective. Unlike previous reviews, our work synthesizes preclinical and clinical evidence while highlighting the novel integration of nanotechnology with bioenhancers and personalized medicine approaches. We further emphasize the emerging concepts of hybrid and smart nanocarriers, which have not yet been systematically discussed, positioning them as next-generation solutions to overcome CBD’s bioavailability challenges and paving the way for precision therapeutics.

Red clover (Trifolium pratense L.) is a rich source of isoflavones with documented antioxidant and skin-protective properties, yet substantial differences in phytochemical composition exist among cultivars. In this study, fourteen T. pratense cultivars were compared with respect to formononetin and biochanin A contents (Milena, Pasieka, Pyza, Milvus, Nemaro, Maro, Larus, Hammon, Vesna, Fregata, Carbo, Forelia, Osimia, and Elanus), and the relationship between isoflavone profiles and skin-related biological activity was evaluated. High-performance liquid chromatography revealed pronounced cultivar-dependent variability with formononetin and biochanin A contents ranging from 1.60 to 7.80 mg/g DW and from 0.69 to 6.44 mg/g DW, respectively. The observed variability was further visualized by principal component analysis. The cultivar with the highest total isoflavone content—Hammon, was selected for biological assessment. Its extract exhibited antioxidant (DPPH IC₅₀ = 0.619 mg/mL; FRAP IC_0.5 = 0.302 mg/mL) and enzyme inhibitory activities (elastase IC₅₀ = 0.602 mg/mL, hyaluronidase IC₅₀ = 22.44 mg/mL), and it significantly enhanced fibroblast migration in an in vitro scratch assay, indicating anti-aging and regenerative potential. These results demonstrate that red clover cultivars differ significantly in their suitability as sources of bioactive isoflavones and highlight the importance of cultivar selection for the development of standardized plant-derived anti-aging ingredients. However, it is worth emphasizing that isoflavones derived from red clover are a valuable group of active compounds with significant potential for topical application as anti-aging and regenerative agents, warranting further formulation development and in vivo validation.

Isoflavones are plant-derived polyphenols with broad biological activity; however, their application in topical formulations is limited by poor aqueous solubility. The aim of this study was to enhance the aqueous solubility of formononetin using a solvent-free hot-melt extrusion (HME) approach and to enable its incorporation into a hydrogel formulation suitable for skin delivery. Amorphous formononetin-based systems were prepared by HME using polymeric carriers and hydroxypropyl-β-cyclodextrin, with and without prior inclusion complex formation. The resulting formulations were characterized using XRPD, DSC, and FT-IR/ATR to assess amorphization and intermolecular interactions. Aqueous solubility and skin permeability were evaluated using solubility testing, PAMPA, and Franz diffusion cells. The optimized amorphous system exhibited a substantial increase in apparent aqueous solubility compared to crystalline formononetin while maintaining comparable permeability. Cyclodextrin–formononetin interactions were effectively generated during the extrusion process, rendering pre-inclusion unnecessary. The selected system was successfully incorporated into a hydrogel matrix. This study demonstrates that solvent-free HME combined with cyclodextrins is an effective strategy for improving formononetin solubility and enabling its application in hydrogel-based topical delivery systems.